Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ELCC 2022 | The latest developments in risk models to predict outcomes following lung cancer surgery

Elena Prisciandaro, MD, University Hospitals Leuven, Leuven, Belgium, discusses the development of risk models as a result of the personalization of medicine. The European Society Objective Score (ESOS) has allowed thoracic surgeons to predict comorbidities and risk factors associated with mortality following lung cancer surgery. Risk models such as ESOS can enable the identification of appropriate therapruitc pathways for each patient undergoing lung resection to thereby enhance patient outcomes. This interview took place during the virtual European Lung Cancer Congress 2022.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.